Emgality Walrus and Jessica Campaign image. For your patients with episodic migraine (4-14 migraine headache days [MHDs] per month), one of these is possible with Emgality<sup>®</sup>. The walrus that went to the moon. The woman who experienced a month of total migraine headache freedom. Emgality can give some patients the chance to be totally migraine-free for a month.<sup>1</sup>

For your patients with 4-14 MHDs per month (EVOLVE-1/EVOLVE-2),

Emgality demonstrated ≥50%, ≥75%, and 100% reductions in the number of monthly MHDs from baseline for a significantly greater mean percentage of patients vs placebo1

Mean percentage of patients meeting defined levels of reduction in monthly MHDs<sup>1</sup>

ap<0.001 vs placebo.


In the REGAIN study, in patients with chronic migraine (≥15 headache days per month), the mean percentage of patients achieving a ≥75% and 100% reduction in monthly MHDs from baseline was not significant vs placebo over Months 1 to 3.1

See study design for EVOLVE-1 and EVOLVE-2

See study design for REGAIN

INDICATION
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


Reference: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 04JUN2019